A Study of Pembrolizumab (+) Berahyaluronidase Alfa (MK-3475A) (Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180)) in Japanese Participants With Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma (R/M cSCC) or Locally Advanced (LA) Unresectable cSCC (MK-3475A-E39)

RECRUITING

Keio University Hospital ( Site 0010), Tokyo

RECRUITING

Nagoya University Hospital ( Site 0003), Nagoya

RECRUITING

Sapporo Medical University Hospital ( Site 0002), Sapporo

RECRUITING

Yokohama City University Hospital ( Site 0016), Yokohama

RECRUITING

Tohoku University Hospital ( Site 0019), Sendai

RECRUITING

Shinshu University Hospital ( Site 0011), Matsumoto

RECRUITING

Niigata Cancer Center Hospital ( Site 0005), Niigata

RECRUITING

Saitama Medical University International Medical Center ( Site 0008), Hidaka

RECRUITING

Shimane University Hospital ( Site 0014), Izumo

RECRUITING

Shizuoka Cancer Center ( Site 0004), Nagaizumi-cho,Sunto-gun

RECRUITING

National Cancer Center Hospital ( Site 0007), Chuo-ku

RECRUITING

Cancer Institute Hospital of JFCR ( Site 0018), Koto

RECRUITING

Chiba University Hospital ( Site 0001), Chiba

RECRUITING

National Hospital Organization Kyushu Cancer Center ( Site 0017), Fukuoka

RECRUITING

National Hospital Organization Kagoshima Medical Center ( Site 0013), Kagoshima

RECRUITING

University Hospital,Kyoto Prefectural University of Medicine ( Site 0012), Kyoto

RECRUITING

Osaka International Cancer Institute ( Site 0009), Osaka

RECRUITING

Wakayama Medical University Hospital ( Site 0015), Wakayama